Enveric Biosciences, Inc. (NASDAQ: ENVB) released its corporate update and reported financial results for the first quarter of 2023 ending March 31, 2023.
Q1 2023 Financial Highlights
- Net loss attributable to shareholders was $4.80 million for the quarter ended March 31, 2023, including $0.56 million in net non-cash expenses, with a basic and diluted loss per share of $2.31, as compared to a net loss of $4.44 with basic and diluted loss per share of $5.34 per share for the quarter ended March 31, 2022.
- Net cash used in operations for the quarter ended March 31, 2023, was $5.14 million consisting of a $4.68 million net loss, adjusted …